Drug class in one race
EGFR/HER1, HER2, HER4 drugs for Non-Small Cell Lung Cancer
3 tracked EGFR/HER1, HER2, HER4 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the EGFR/HER1, HER2, HER4 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 41 Phase 3
Head-to-head evidence: Afatinib vs Dacomitinib PF-00299804 · Afatinib vs Pyrotinib · Dacomitinib PF-00299804 vs Pyrotinib